US 7,008,938 B2Granted

Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient

AssigneeNokia Corporation

InventorsKazuyuki Ohmoto, Iori Itagaki

Life of this patent

Estimating the term…

Abstract

A benzene-fused heteroring derivative of formula (I) wherein all symbols are the same as described in the specification, and a non-toxic salt thereof. The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of immune diseases (autoimmune diseases, infectious diseases, etc.), inflammatory diseases (inflammatory bowel diseases, multiple cerebrosclerosis, arthritis, etc.), nerve degeneration diseases (Alzheimer's disease, muscular dystrophy, etc.), bone resorption diseases (osteoporosis, etc.), respiratory system diseases, diabetes, shock, etc.

Claims18

Dependent claims

A compound of formula (I),

wherein R is
(i) hydrogen,
(ii) C1-8 alkyl,
(iii) CycA,
(iv) C1-8 alkyl substituted with a group selected from halogen atom, CycA, nitro, CF3 and cyano,
CycA is mono-, bi- or tri-cyclic C3-15 carboring or mono-, bi- or tri-cyclic 3-15 membered heteroring comprising 1-4 of nitrogen, 1-2 of oxygen and/or 1 of sulfur;
R16 is
(1) C1-8 alkyl,
(2) C2-8 alkenyl,
(3) C2-8 alkynyl,
(4) CycA or
(5) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted with a group selected from halogen, nitro, CF3, cyano, CycA, NR18R19 and —NHC(O)-CycA;
R17, R18 and R19 each independently are, hydrogen or C1-4 alkyl,
AA1 is
(i) a single bond, or
wherein R1 and R2 are the same or different and represent
(i) hydrogen,
(ii) C1-8 alkyl,
(iii) CycA or
(iv) C1-8 alkyl substituted with 1-5 of group selected from the following (1)-(8):
(1) —NR21R22,
(2)—OR23,
(3) —SR24,
(4) —COR25,
(5) —NR26CONR21R22,
(6) guanidino,
(7) CycA,
(8) —NR26 SO2R21;
or
R1 and R2 are taken together to form C2-8 alkylene wherein one carbon atom may be replaced by oxygen, sulfur or —NR20— and the alkylene may be substituted with —NR21R22 or —OR23,
R20 is hydrogen, C1-4 alkyl, —COO—(C1-4 alkyl), phenyl or C1-4 alkyl substituted with phenyl,
R21, R22, R23, R24 and R26 are the same or different and represent hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl,
R25 is C1-4 alkyl, phenyl, —NR21R22, wherein all symbols have the same meanings as above, —OR23, wherein R23 is the same meaning as above, or C1-4 alkyl substituted with phenyl,
R3 is hydrogen, C1-8 alkyl, phenyl or C1-8 alkyl substituted with phenyl or
R3 is taken together with R1 to form C2-6 alkylene, wherein one carbon atom may be replaced by oxygen, sulfur or —NR20— and the alkylene may be substituted with —NR21R22 or —OR23, or
when AA1 is
AA1 and R may be taken together to form
is a 5-13 membered mono- or bi-cyclic heteroring and the other symbols have the same meanings as above,
AA2 is
(i) a single bond,
wherein R4 and R5 are the same or different and represent
(1) hydrogen,
(2) C1-8 alkyl,
(3) CycA or
(4) C1-8 alkyl substituted with 1-5 of group selected from the following (a)-(h):
(a) —NR41R42, (b) —OR43, (c) —SR44, (d) —COR45, (e) —NR46CONR41R42, (f) guanidino, (g) CycA, (h) —NR46SO2R41;
or
R4 and R5 are taken together to form C2-8 alkylene, wherein one carbon atom may be replaced by oxygen, sulfur or —NR40— and the alkylene may be substituted with —NR41R42 or —OR43,
R40 is hydrogen, C1-4 alkyl, —COO—(C1-4 alkyl), phenyl or C1-4 alkyl substituted with phenyl,
R41, R42, R43, R44 and R46 are the same or different and represent hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl,
R45 is C1-4 alkyl, phenyl, —NR41R42, wherein all symbols have the same meaning as above, —OR43, wherein R43 has the same meaning as above, or C1-4 alkyl substituted with phenyl,
R6 is hydrogen, C1-8 alkyl, phenyl or C1-8 alkyl substituted with phenyl or
R6 is taken together with R4 to form C2-6 alkylene, wherein one carbon atom may be replaced by oxygen, sulfur or —NR40— and the alkylene may be substituted with —NR41R42 or —OR43,
R48 is hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl or
when AA1 is a single bond, R48 and R may be taken together to form C2-6 alkylene, wherein one carbon atom may be replaced by oxygen, sulfur or —NR47—, wherein R47 is hydrogen or C1-4 alkyl,
CycC is a 3-17 membered mono- or bi-cyclic heteroring,
CycD is a C3-14 mono- or bi-cyclic carboring or a 3-14 membered mono- or bi-cyclic heteroring, or
AA2 and AA1 are taken together to form
wherein CycE is a 4-18 membered mono- or bi-cyclic heteroring, CycF is a 5-8 membered monocyclic heteroring, and the other symbols have the same meanings as above,
R7 and R8 are the same or different and represent
(i) hydrogen,
(ii) C1-8 alkyl,
(iii) CycA or
(iv) C1-8 alkyl substituted with 1-5 of group selected from the following (1)-(8);
(1) —NR61R62, (2) —OR63, (3) —SR64, (4) —COR65, (5)—NR66CONR61R62, (6) guanidino, (7) CycA, (8) —NR66SO2R61, or
R7 and R8 are taken together to form C2-8 alkylene, wherein one carbon atom may be replaced by oxygen, sulfur or —NR60— and the alkylene may be substituted with —NR61R62 or —OR63,
R60 is hydrogen, C1-4 alkyl, —COO—(C1-4 alkyl), phenyl or C1-4 alkyl substituted with phenyl,
R61, R62, R63, R64 and R66 are the same or different to represent hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl, R65 is C1-4 alkyl, phenyl, —NR61R62, wherein all symbols have the same meanings as above, —OR63, wherein R63 has the same meaning as above, or C1-4 alkyl substituted with phenyl,
R9 is hydrogen, C1-8 alkyl, phenyl or C1-8 alkyl substituted with phenyl or
R9 is taken together with R7 to form C2-6 alkylene, wherein one carbon atom may be replaced by oxygen, sulfur or —NR60— and the alkylene may be substituted with —NR61R62 or —OR63,
r is an integer of 1-4,
proviso that when r=1,
in the ring represented by (i), (ii) and (iii), one or two saturated carbon atom may be replaced by
(1) oxygen,
(2) —S(O)s— or
(3) —NR83—,
wherein s is 0 or an integer of 1-2,
R83 is
(a) hydrogen,
(b) C1-8 alkyl,
(c) CycA or
(d) C1-8 alkyl substituted with 1-5 of group selected from CycA, guanidino, —COR68, —NR69R70, cyano and —P(O)(OR75)2,
R68 is C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl,
R69 and R70 are the same or different to represent hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl,
R75 is hydrogen, C1-8 alkyl, phenyl or C1-4 alkyl substituted with 1-5 of phenyl, cyano or halogen,
and the rings of (i), (ii) and (ill) may be fused with C5-8 carboring or a 5-8 membered heteroring containing 1-2 of nitrogen, 1 of oxygen and/or 1 of sulfur,
q is an integer of 0 or 1 to 5,
R10 is
(i) C1-8 alkyl,
(ii) C2-8 alkenyl,
(iii) C2-8 alkynyl,
(iv) halogen,
(v) CycA,
(vi) —COR71,
(vii) —NR72R73,
(viii) —OR74, or
(ix) C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl substituted with 1-5 of group selected from the following <1>-<7>:
<1> CycA, <2> guanidino, <3> —COR71, <4> —NR72R73, <5> —OR74, <6> cyano and <7> —P(O)(OR82)2,
wherein R82 is hydrogen, C1-8 alkyl, C1-4 alkyl substituted with 1-5 of phenyl, cyano or halogen,
R71 is
(1) C1-8 alkyl,
(2) CycA,
(3) —NR72R73,
(4) —OR74 or
(5) C1-8 alkyl substituted with CycA,
R72 and R73 are the same or different and represent
(1) hydrogen,
(2) C1-8 alkyl,
(3) CycA or
(4) C1-8 alkyl substituted with 1-5 of group selected from the following (a)-(f):
(a) CycA,
(b) guanidino,
(c) —NR77R78, wherein R77 and R78 are the same or different and represent hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl,
(d) —OR77, wherein R77 has the same meaning as above,
(e) —COR76, wherein R76 is C1-4 alkyl, phenyl, —NR77R78, wherein all symbols have the same meanings as above, —OR77, wherein R77 has the same meaning as above, or C1-4 alkyl substituted with phenyl, and
(f) cyano;
R74 is
(1) hydrogen,
(2) C1-8 alkyl,
(3) CycA, or
(4) C1-8 alkyl substituted with 1-5 of groups selected from the following (a)-(h), wherein one carbon atom may be replaced by oxygen, sulfur atom or —NR84—;
(a) CycA,
(b) guanidino,
(c) —SiR79R80R81, wherein R79, R80 and R81 are the same or different to represent, C1-8 alkyl, phenyl or C1-8 alkyl substituted with phenyl,
(d) —NR77R78 wherein all symbols have the same meanings as above,
(e) —OR77, wherein R77 has the same meaning as above,
(f) —COR76, wherein R76 has the same meaning as above,
(9) cyano,
(h) —P(O)(OR82)2, wherein all symbols have the same meanings as above;
with the proviso that CycA in R, R1, R2, R4, R5, R7, R8, R10, R16, R71, R72, R73, R74, R83 are the same or different, and CycA, CycB, CycC, CycD, CycE and CycF may be, each independently, substituted with 1-5 of R27:
R27 is
(1) C1-8 alkyl,
(2) halogen,
(3) —NR11R12,
(4) —OR13,
(5) C5-10 mono- or bi-cyclic carboring,
(6) nitro,
(7) CF3,
(8) cyano,
(9) 5-10 membered mono- or bi-cyclic heteroring,
(10) —SR14,
(11) —COR15,
(12) oxo,
(13) —SO2R15,
(14) —OCF3 or
(15) C1-8 alkyl substituted with 1-5 of group selected from the following (a)-(m):
(a) halogen,
(b) —NR11R12,
(c) —OR13,
(d) C5-10 mono- or bi-cyclic carboring,
(e) nitro,
(f) CF3,
(g) cyano,
(h) 5-10 mono- or bi-cyclic heteroring,
(j) —SR14,
(k) —COR15,
(l) —SO2R15,
(m) —OCF3,
wherein R11 and R12 are the same or different and represent, hydrogen, C1-4 alkyl, —COO—(C1-4 alkyl), phenyl or C1-4 substituted with phenyl,
R13 and R14 are the same or different and represent, hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl,
R15 is C1-4 alkyl, phenyl, —NR11R12, wherein all symbols have the same meanings as above, —OR13, wherein R13 has the same meaning as above, or C1-4 alkyl substituted with phenyl,
or a non-toxic salt thereof.

159 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/901,263Filed 29 Jul 2004 · division
Priority: JP 2000-01704526 Jan 2000
Published: US 2005/0009755 A113 Jan 2005
Granted: 7 Mar 2006
Term ends: Not estimatedThe source records don’t support an estimate.

Classification49 codes

C07D 223/16
Condensed with carbocyclic rings or ring systems: benzazepines; Hydrogenated benzazepines
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 1/16
Drugs for disorders of the alimentary tract or the digestive system: for liver or gallbladder disorders, e.g. hepatoprotective agents,…
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics

Family

PCT/JP01/00473Parent of this division · filed 25 Jan 2001
US 2005/0009755 A1Pre-grant publication · published 13 Jan 2005
Application10/181,713Parent of this division
US 6,809,092 B2Parent of this division
US 2003/0162964 A1Published application
US 7,008,938 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

A compound of formula (I),

wherein R is
(i) hydrogen,
(ii) C1-8 alkyl,
(iii) CycA,
(iv) C1-8 alkyl substituted with a group selected from halogen atom, CycA, nitro, CF3 and cyano,
CycA is mono-, bi- or tri-cyclic C3-15 carboring or mono-, bi- or tri-cyclic 3-15 membered heteroring comprising 1-4 of nitrogen, 1-2 of oxygen and/or 1 of sulfur;
R16 is
(1) C1-8 alkyl,
(2) C2-8 alkenyl,
(3) C2-8 alkynyl,
(4) CycA or
(5) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted with a group selected from halogen, nitro, CF3, cyano, CycA, NR18R19 and —NHC(O)-CycA;
R17, R18 and R19 each independently are, hydrogen or C1-4 alkyl,
AA1 is
(i) a single bond, or
wherein R1 and R2 are the same or different and represent
(i) hydrogen,
(ii) C1-8 alkyl,
(iii) CycA or
(iv) C1-8 alkyl substituted with 1-5 of group selected from the following (1)-(8):
(1) —NR21R22,
(2)—OR23,
(3) —SR24,
(4) —COR25,
(5) —NR26CONR21R22,
(6) guanidino,
(7) CycA,
(8) —NR26 SO2R21;
or
R1 and R2 are taken together to form C2-8 alkylene wherein one carbon atom may be replaced by oxygen, sulfur or —NR20— and the alkylene may be substituted with —NR21R22 or —OR23,
R20 is hydrogen, C1-4 alkyl, —COO—(C1-4 alkyl), phenyl or C1-4 alkyl substituted with phenyl,
R21, R22, R23, R24 and R26 are the same or different and represent hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl,
R25 is C1-4 alkyl, phenyl, —NR21R22, wherein all symbols have the same meanings as above, —OR23, wherein R23 is the same meaning as above, or C1-4 alkyl substituted with phenyl,
R3 is hydrogen, C1-8 alkyl, phenyl or C1-8 alkyl substituted with phenyl or
R3 is taken together with R1 to form C2-6 alkylene, wherein one carbon atom may be replaced by oxygen, sulfur or —NR20— and the alkylene may be substituted with —NR21R22 or —OR23, or
when AA1 is
AA1 and R may be taken together to form
is a 5-13 membered mono- or bi-cyclic heteroring and the other symbols have the same meanings as above,
AA2 is
(i) a single bond,
wherein R4 and R5 are the same or different and represent
(1) hydrogen,
(2) C1-8 alkyl,
(3) CycA or
(4) C1-8 alkyl substituted with 1-5 of group selected from the following (a)-(h):
(a) —NR41R42, (b) —OR43, (c) —SR44, (d) —COR45, (e) —NR46CONR41R42, (f) guanidino, (g) CycA, (h) —NR46SO2R41;
or
R4 and R5 are taken together to form C2-8 alkylene, wherein one carbon atom may be replaced by oxygen, sulfur or —NR40— and the alkylene may be substituted with —NR41R42 or —OR43,
R40 is hydrogen, C1-4 alkyl, —COO—(C1-4 alkyl), phenyl or C1-4 alkyl substituted with phenyl,
R41, R42, R43, R44 and R46 are the same or different and represent hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl,
R45 is C1-4 alkyl, phenyl, —NR41R42, wherein all symbols have the same meaning as above, —OR43, wherein R43 has the same meaning as above, or C1-4 alkyl substituted with phenyl,
R6 is hydrogen, C1-8 alkyl, phenyl or C1-8 alkyl substituted with phenyl or
R6 is taken together with R4 to form C2-6 alkylene, wherein one carbon atom may be replaced by oxygen, sulfur or —NR40— and the alkylene may be substituted with —NR41R42 or —OR43,
R48 is hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl or
when AA1 is a single bond, R48 and R may be taken together to form C2-6 alkylene, wherein one carbon atom may be replaced by oxygen, sulfur or —NR47—, wherein R47 is hydrogen or C1-4 alkyl,
CycC is a 3-17 membered mono- or bi-cyclic heteroring,
CycD is a C3-14 mono- or bi-cyclic carboring or a 3-14 membered mono- or bi-cyclic heteroring, or
AA2 and AA1 are taken together to form
wherein CycE is a 4-18 membered mono- or bi-cyclic heteroring, CycF is a 5-8 membered monocyclic heteroring, and the other symbols have the same meanings as above,
R7 and R8 are the same or different and represent
(i) hydrogen,
(ii) C1-8 alkyl,
(iii) CycA or
(iv) C1-8 alkyl substituted with 1-5 of group selected from the following (1)-(8);
(1) —NR61R62, (2) —OR63, (3) —SR64, (4) —COR65, (5)—NR66CONR61R62, (6) guanidino, (7) CycA, (8) —NR66SO2R61, or
R7 and R8 are taken together to form C2-8 alkylene, wherein one carbon atom may be replaced by oxygen, sulfur or —NR60— and the alkylene may be substituted with —NR61R62 or —OR63,
R60 is hydrogen, C1-4 alkyl, —COO—(C1-4 alkyl), phenyl or C1-4 alkyl substituted with phenyl,
R61, R62, R63, R64 and R66 are the same or different to represent hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl, R65 is C1-4 alkyl, phenyl, —NR61R62, wherein all symbols have the same meanings as above, —OR63, wherein R63 has the same meaning as above, or C1-4 alkyl substituted with phenyl,
R9 is hydrogen, C1-8 alkyl, phenyl or C1-8 alkyl substituted with phenyl or
R9 is taken together with R7 to form C2-6 alkylene, wherein one carbon atom may be replaced by oxygen, sulfur or —NR60— and the alkylene may be substituted with —NR61R62 or —OR63,
r is an integer of 1-4,
proviso that when r=1,
in the ring represented by (i), (ii) and (iii), one or two saturated carbon atom may be replaced by
(1) oxygen,
(2) —S(O)s— or
(3) —NR83—,
wherein s is 0 or an integer of 1-2,
R83 is
(a) hydrogen,
(b) C1-8 alkyl,
(c) CycA or
(d) C1-8 alkyl substituted with 1-5 of group selected from CycA, guanidino, —COR68, —NR69R70, cyano and —P(O)(OR75)2,
R68 is C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl,
R69 and R70 are the same or different to represent hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl,
R75 is hydrogen, C1-8 alkyl, phenyl or C1-4 alkyl substituted with 1-5 of phenyl, cyano or halogen,
and the rings of (i), (ii) and (ill) may be fused with C5-8 carboring or a 5-8 membered heteroring containing 1-2 of nitrogen, 1 of oxygen and/or 1 of sulfur,
q is an integer of 0 or 1 to 5,
R10 is
(i) C1-8 alkyl,
(ii) C2-8 alkenyl,
(iii) C2-8 alkynyl,
(iv) halogen,
(v) CycA,
(vi) —COR71,
(vii) —NR72R73,
(viii) —OR74, or
(ix) C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl substituted with 1-5 of group selected from the following <1>-<7>:
<1> CycA, <2> guanidino, <3> —COR71, <4> —NR72R73, <5> —OR74, <6> cyano and <7> —P(O)(OR82)2,
wherein R82 is hydrogen, C1-8 alkyl, C1-4 alkyl substituted with 1-5 of phenyl, cyano or halogen,
R71 is
(1) C1-8 alkyl,
(2) CycA,
(3) —NR72R73,
(4) —OR74 or
(5) C1-8 alkyl substituted with CycA,
R72 and R73 are the same or different and represent
(1) hydrogen,
(2) C1-8 alkyl,
(3) CycA or
(4) C1-8 alkyl substituted with 1-5 of group selected from the following (a)-(f):
(a) CycA,
(b) guanidino,
(c) —NR77R78, wherein R77 and R78 are the same or different and represent hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl,
(d) —OR77, wherein R77 has the same meaning as above,
(e) —COR76, wherein R76 is C1-4 alkyl, phenyl, —NR77R78, wherein all symbols have the same meanings as above, —OR77, wherein R77 has the same meaning as above, or C1-4 alkyl substituted with phenyl, and
(f) cyano;
R74 is
(1) hydrogen,
(2) C1-8 alkyl,
(3) CycA, or
(4) C1-8 alkyl substituted with 1-5 of groups selected from the following (a)-(h), wherein one carbon atom may be replaced by oxygen, sulfur atom or —NR84—;
(a) CycA,
(b) guanidino,
(c) —SiR79R80R81, wherein R79, R80 and R81 are the same or different to represent, C1-8 alkyl, phenyl or C1-8 alkyl substituted with phenyl,
(d) —NR77R78 wherein all symbols have the same meanings as above,
(e) —OR77, wherein R77 has the same meaning as above,
(f) —COR76, wherein R76 has the same meaning as above,
(9) cyano,
(h) —P(O)(OR82)2, wherein all symbols have the same meanings as above;
with the proviso that CycA in R, R1, R2, R4, R5, R7, R8, R10, R16, R71, R72, R73, R74, R83 are the same or different, and CycA, CycB, CycC, CycD, CycE and CycF may be, each independently, substituted with 1-5 of R27:
R27 is
(1) C1-8 alkyl,
(2) halogen,
(3) —NR11R12,
(4) —OR13,
(5) C5-10 mono- or bi-cyclic carboring,
(6) nitro,
(7) CF3,
(8) cyano,
(9) 5-10 membered mono- or bi-cyclic heteroring,
(10) —SR14,
(11) —COR15,
(12) oxo,
(13) —SO2R15,
(14) —OCF3 or
(15) C1-8 alkyl substituted with 1-5 of group selected from the following (a)-(m):
(a) halogen,
(b) —NR11R12,
(c) —OR13,
(d) C5-10 mono- or bi-cyclic carboring,
(e) nitro,
(f) CF3,
(g) cyano,
(h) 5-10 mono- or bi-cyclic heteroring,
(j) —SR14,
(k) —COR15,
(l) —SO2R15,
(m) —OCF3,
wherein R11 and R12 are the same or different and represent, hydrogen, C1-4 alkyl, —COO—(C1-4 alkyl), phenyl or C1-4 substituted with phenyl,
R13 and R14 are the same or different and represent, hydrogen, C1-4 alkyl, phenyl or C1-4 alkyl substituted with phenyl,
R15 is C1-4 alkyl, phenyl, —NR11R12, wherein all symbols have the same meanings as above, —OR13, wherein R13 has the same meaning as above, or C1-4 alkyl substituted with phenyl,
or a non-toxic salt thereof.

159 more elements

Facts

Application

10/901,263Filed 29 Jul 2004 · division

Priority

JP 2000-01704526 Jan 2000

Published

US 2005/0009755 A113 Jan 2005

Granted

7 Mar 2006

Term ends

Not estimatedThe source records don’t support an estimate.

Classification49 codes

C07D 223/16
Condensed with carbocyclic rings or ring systems: benzazepines; Hydrogenated benzazepines
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 1/16
Drugs for disorders of the alimentary tract or the digestive system: for liver or gallbladder disorders, e.g. hepatoprotective agents,…
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics

Family

PCT/JP01/00473Parent of this division · filed 25 Jan 2001

US 2005/0009755 A1Pre-grant publication · published 13 Jan 2005

Application10/181,713Parent of this division

US 6,809,092 B2Parent of this division

US 2003/0162964 A1Published application

US 7,008,938 B2This patent

From the US filing history. Foreign family members aren’t listed.